Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SOUTH AMERICA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources
PubMed1993

Preparación toxoide a partir de la fracción hemorrágica del veneno de Bothrops asper (serpiente de América Central y del Sur) (Toxoid preparation from hemorrhagic fraction of the venom from Bothrops asper (snake from Central and South America).

A technique is described for preparing a toxoid from the hemorrhagic fraction of the Bothrops asper venom. This method conserves a high degree of immunogenicity although it eliminates lethal effects. None of the animals vaccinated with the toxoid from this fraction had hemorrhagic lesions after they were injected the venom from the hemorrhagic fraction.

Animals↗
PubMed1998

Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.

Gatifloxacin (formerly AM-115) is a new 8-methoxy fluoroquinolone with an expanded spectrum against Gram-positive cocci and some anaerobes. To assess this new agent's activity, a collection of 1,676 Gram-positive cocci were selected for resistance to ciprofloxacin (> or = 4 micrograms/mL) and tested against gatifloxacin and 18 other compounds by reference broth microdilution methods. The strains (approximately 23,000 total isolates from the SENTRY Antimicrobial Surveillance Program) were from significant blood stream, respiratory tract, wound, and urinary tract infections in patients in North (38 hospitals) and South (10 hospitals) America. Against Enterococcus faecalis and E. faecium, gatifloxacin inhibited only 16% and 10% of strains compared with 12% and 5% for recently released trovafloxacin, respectively. Among Staphylococcus aureus (90% oxacillin-resistant) strains, gatifloxacin was more active (67% susceptible at < or = 4 micrograms/mL) than trovafloxacin (59%) or sparfloxacin (4%). Gatifloxacin had a wider spectrum than trovafloxacin against coagulase-negative staphylococci especially S. epidermidis, 2% versus 58% resistance. The glycopeptides, chloramphenicol and rifampin were most active. Against all genus/species groups with more than 100 sample strains (1,566), high-level resistance to gatifloxacin and trovafloxacin (> 4 micrograms/mL) was not significantly different (41.7% versus 39.1%; p > 0.05). Emerging resistance to the fluoroquinolones remains a clinical problem among Gram-positive species, and gatifloxacin seems to be active in vitro against many of these contemporary strains isolated in the Americas.

Anti-Infective Agents↗